SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · IEX Real-Time Price · USD
9.33
+0.27 (2.98%)
At close: Jul 19, 2024, 4:00 PM
9.37
+0.04 (0.43%)
Pre-market: Jul 22, 2024, 7:23 AM EDT
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.
Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.
Country | United States |
Founded | 1995 |
IPO Date | Sep 9, 1997 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 45 |
CEO | Dr. Diem Nguyen M.B.A., Ph.D. |
Contact Details
Address: 31 East 62nd Street New York, New York 10065 United States | |
Phone | 212-672-9100 |
Website | siga.com |
Stock Details
Ticker Symbol | SIGA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001010086 |
CUSIP Number | 826917106 |
ISIN Number | US8269171067 |
Employer ID | 13-3864870 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Diem Nguyen M.B.A., Ph.D. | Chief Executive Officer and Director |
Daniel J. Luckshire | Executive Vice President, Chief Financial Officer and Secretary |
Dr. Dennis E. Hruby | Executive Vice President and Chief Scientific Officer |
Dr. Jay K. Varma M.D. | Executive Vice President, Chief Medical Officer and Director |
Tove C. Bolken | Senior Vice President of Operations and Chief Supply Chain Officer |
Herb Vloedman | Senior Vice President and Chief Information Officer |
Lawrence R. Miller Esq., J.D. | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 19, 2024 | 8-K | Current Report |
Jun 13, 2024 | 8-K | Current Report |
May 7, 2024 | 10-Q | Quarterly Report |
May 7, 2024 | 8-K | Current Report |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 1, 2024 | 8-K | Current Report |
Mar 12, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 8-K | Current Report |